Julia L Glade-Bender

Learn More
BACKGROUND Outcomes remain poor for children after relapse of acute lymphoblastic leukemia (ALL), especially after early marrow relapse. Bortezomib is a proteasome inhibitor with in vitro synergy(More)
BACKGROUND To evaluate the neuropsychological late effects amongst survivors treated on the Head Start II protocol between 1997 and 2003. PROCEDURES Forty-nine patients (mean age 2.9 years)(More)
Sunitinib is an oral tyrosine kinase inhibitor of VEGF, PDGF, c-KIT, and flt-3 receptors. A pediatric phase I study of sunitinib capsules identified the maximum tolerated dose as 15 mg/m2/day. This(More)
  • 1